) announced encouraging top-line data from a phase IIIb study
evaluating Genotropin for increasing height in
small-for-gestational-age (SGA) children aged between 24 and 30
The controlled, multi-center,, randomized phase IIIb study (n =
43) was aimed at gathering additional insight into the safety and
efficacy of Genotropin in born SGA children who do not achieve
catch-up growth by two years of age.
The study met its primary endpoint. After 24 months,
statistically significant increases in height from baseline was
observed in the Genotropin arm as compared to those who did not
receive Genotropin. Results were measured by the height standard
We note that Genotropin is already approved in the U.S. for
treating children who fail to make enough growth hormone on their
own, have the genetic condition known as Prader-Willi syndrome,
were born smaller than most other babies, have Turner syndrome (a
genetic disorder) or have idiopathic short stature. The U.S. Food
and Drug Administration (FDA) has also approved the drug for the
treatment adults with growth hormone deficiency. Genotropin
generated revenues of $772 million in 2013.
Pfizer carries a Zacks Rank #3 (Hold). Pfizer will be hit by a
series of patent expiries including that of Aricept, Revatio and
Viagra until 2015. The loss of patent exclusivity in the coming
years will make it challenging for the company to drive top-line
growth. The company expects loss of exclusivity and other factors
to cut 2014 revenues by about $3 billion.
Investors looking for better-ranked stocks in the biopharma
sector may consider companies like
Questcor Pharmaceuticals, Inc.
), all of which carry a Zacks Rank #1 (Strong Buy).
ALKERMES INC (ALKS): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
QUESTCOR PHARMA (QCOR): Free Stock Analysis
SHIRE PLC-ADR (SHPG): Free Stock Analysis
To read this article on Zacks.com click here.